---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-119408"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:18:12.343850+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kalaris Q1 net loss $10.2M ($2.52/shr); cash $101M; TH103 Phase 1 data expected Q4 2025

## Summary
- Net loss of $10.2M for Q1 2025 vs $3.4M for Q1 2024; diluted EPS loss $2.52.
- Cash and equivalents $101.0M as of March 31, 2025, expected to fund operations into Q4 2026.
- R&D expenses $6.0M (up from $2.0M YoY) driven by TH103 Phase 1 trial initiation.
- Phase 1 trial of TH103 for nAMD actively enrolling; initial clinical data expected Q4 2025.
- Completed merger with AlloVir in March 2025; appointed Leone Patterson to Board and Audit Committee.

## SEC filing metadata
- accession: 0001193125-25-119408
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/0001193125-25-119408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-119408
- JSON: https://secwatch.observer/filing/0001193125-25-119408.json
- Plain text: https://secwatch.observer/filing/0001193125-25-119408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.